Voyager Therapeutics IPO

11/11/2015

IPO

$70,000,000

We currently expect to use the net proceeds from the offering as follows: $25.0 million to fund the costs of future clinical development, including later-stage clinical trials, and manufacturing of VY-AADC01 for our program for advanced Parkinson's disease; $30.0 million to fund the costs of additional preclinical development, manufacturing, clinical development, including Phase 1 and later-stage clinical trials, and internal personnel costs for our preclinical programs, including VY-SOD101 for the treatment of a monogenic form of ALS, VY-FXN01 for the treatment of Friedreich's ataxia, VY-HTT01 for the treatment of Huntington's disease and VY-SMN101 for the treatment of SMA; and the remainder to fund working capital and other general corporate purposes, which may include funding for new research and development activities, the hiring of additional personnel, capital expenditures and the costs of operating as a public company.

Publicly-held

Biopharmaceutical

75 Sidney St.
Cambridge, MA 02139
USA

Voyager Therapeutics (NASDAQ: VYGR) is developing life-changing gene therapies for fatal and debilitating diseases of the central nervous system. Our founders include scientific and clinical leaders in the fields of adeno-associated virus (AAV) gene therapy, expressed RNA interference and neuroscience.